Product Images Losartan Potassium

Losartan Potassium is a tablet with a strength of 100 mg. The package contains 90 tablets and is manufactured by Aurohindo, Nagar, India 509302. The medicine should be kept out of reach of children and the directions for use are specified in the package insert. The medicine should be stored within the temperature range of 20-25°C (58-77°F), with permitted excursions to 15-30°C (59-86°F) [See USP]. The medicine is repackaged by RemedyRepack Inc., Indiana, PA 15701. The lot number, medication expiry date, and package code are not available.*

Losartan Potassium is a tablet medication with 100mg strength and comes in a pack of 30. It is manufactured by Aurohindo in Nagar, India (source NDC: 65862-0203-99). The medication should be stored between 20-25°C (58-77°F) and can be kept at 15-30°C (59-86°F) during short excursions. The product should be kept away from children at all times. It is important to refer to the package insert for directions for use. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA 15701 with an NDC number of 70518-0718-02 for RX use only. The lot number and expiration date are not available in the provided text.*

Losartan Potassium is a tablet that contains 100 mg of the active ingredient. The bottle contains 30 tablets and is for a prescription-only use. The pills come in a package with an NDC number of 70518-0718-00 5 and a LOT number, while the manufacturer is Aurohindo, Nagar, India 509302. The directions for use are in the package insert, and the medication should be kept out of reach of children. It should be stored at 20-25°C [58-77°F) with excursions permitted to 15-30°C (59-86°F)[See USP]. The medication has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*

The text seems to be a medical study about the effect of Atenolol and Losartan Potassium on risk reduction. The study shows an adjusted risk reduction percentage of 13% and lists the study months from 6 to 66. It is not clear what the study is about specifically or what the p-value is, which is cut off.*

This text is not-available for generating a useful description as it only consists of a list of two medication names and a chart indicating the percentage of patients with fatal/non-fatal stroke over a period of 66 months.*

This appears to be a table showing demographic subgroups and primary endpoint events related to certain factors such as age, gender, race, and history of VD. However, without more context or a clear explanation of the primary endpoint events and factors, it is difficult to provide a more specific description.*